Navigation Links
Jury Returns Verdict in VNUS' Patent Infringement Lawsuit With Total Vein Systems and biolitec Finding Some Patent Claims Invalid and Some Infringed
Date:12/9/2010

HOUSTON, Dec. 9, 2010 /PRNewswire/ -- After a lengthy seven-week trial in VNUS' lawsuit against Total Vein Solutions, LLC d/b/a Total Vein Systems ("TVS") and biolitec, Inc. ("biolitec"), a federal jury in San Francisco has returned a verdict finding invalidity of many of the claims of VNUS' patents, and infringement of others.  

"TVS agrees with the jury's findings that certain claims in VNUS' '084, '803 and '355 patents were invalid as "obvious," but is displeased with the jury's verdict of infringement and damages."  Tyri Schiek, President and co-owner of TVS commented, "It has always been and remains our position that TVS does not infringe anyone's patents by selling unpatented, standard medical supplies.  We believe all of the VNUS method patents are invalid."   David Centanni, co-owner and CEO of TVS, added that "we disagree with the jury's conclusion on infringement and think the jury's findings on damages were grossly inflated.  TVS will continue business as usual and is confident that those findings of the jury that were in error will be overturned, either by the trial court or at the appellate level.  Total Vein remains dedicated to providing the highest quality medical products to physicians and clinics at fair and equitable prices."

VNUS sued TVS, among others, in 2008, for indirect patent infringement, by way of contributory and induced infringement, relating to TVS' sales of laser fibers, laser consoles, introducer kits and procedure packs.  The patents at issue do not cover a particular product or device, but instead claim a method of performing endovenous ablation with vein compression.  

TVS has steadfastly denied that its sales of unpatented products amount to infringing conduct.  TVS also noted that the patents do not adequately enable doctors to perform the methods using laser or microwave energy modalities without "undue experimentation," despite claiming such.  Moreover, TVS and biolitec argued that a variety of publications show that the same endovenous ablation methods existed long before, and that VNUS' claimed procedure is merely an obvious variant of such earlier described methods.  

TVS expects that it will file all necessary motions in the trial court to overturn the portions of the jury's decision that were in error, and will appeal where necessary.  Contact: David Centanni, CEO and co-ownerTyri Schiek, President and co-owner888 868-8346
'/>"/>

SOURCE Total Vein Solutions, LLC d/b/a Total Vein Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Blood Donors Needed as School, Fall Season Returns
2. 2nd Annual Orthopedic Design & Technology Forum Returns April 28 to the FedEx Institute of Technology, University of Memphis
3. Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions
4. Molecular Devices Returns to Life Sciences Marketplace
5. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day
6. Segal McCambridge Singer & Mahoney, Ltd. and Greenberg Traurig, LLP Obtain Three Defense Verdicts for I-Flow in Oregon Infusion Pump Cases
7. Jury Verdict Against Novartis Pharmaceuticals For Retaliating Against Drug Sales Rep Who Took Maternity Leave
8. Maryland Woman Thankful for Wyeth Verdicts
9. Published Study Shows VNUS ClosureFAST(TM) System Significantly Superior to Laser for Varicose Vein Treatment
10. NHS National Innovation Centre Cites VNUS Closure(R) Procedure as Select Innovative Technology
11. Study Data Shows VNUS ClosureFAST(TM) Catheter More than 96% Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 2016  HemaFlo Therapeutics, Inc. announced today that the United ... Number 9,119,880 covering the use of NephroFlow to treat acute ... HemaFlo,s founder, said, "We are pleased to secure our rights ... Peterson , PhD, HemaFlo,s founder, said, "We are pleased to ... --> Dale Peterson , PhD, HemaFlo,s founder, said, ...
(Date:2/8/2016)... , Feb. 8, 2016  Sangamo BioSciences, Inc. ... genome editing, announced that the U.S. Food and ... New Drug (IND) application for SB-318, a single ... for Mucopolysaccharidosis Type I (MPS I). The SB-318 ... to initiate a Phase 1/2 clinical study (SB-318-1502) ...
(Date:2/8/2016)... , 8. Februar 2016  LivaNova, ... heute eine Infografik mit dem Titel „Epilepsy ... Welt), mit der der Krankheit gegenüber ein ... dazu ermutigen soll, Medikamentenresistenz bei Epilepsie auf ... allgemeinen Diskussion zu machen. Mithilfe der neuen ...
Breaking Medicine Technology:
(Date:2/8/2016)... Indianapolis, IN (PRWEB) , ... February 08, 2016 ... ... serving the Indianapolis, IN metro area, has selected the latest beneficiary of their ... nonprofit organization dedicated to preventing bullying in area schools. Donations are now being ...
(Date:2/8/2016)... San Francisco, CA (PRWEB) , ... February 08, 2016 , ... ... helped raise $792,000 to help combat pancreatic cancer. , Gary D. Radine, who recently ... who also was the American Cancer Society’s 2015 CEO of the Year , ...
(Date:2/8/2016)... ... February 08, 2016 , ... Remember the old saying “rub some ... to Perry A~, author of “Calcium Bentonite Clay” the health benefits of integrating clay ... and detoxifying the body. , A former motivational speaker, Perry A~ has since dedicated ...
(Date:2/8/2016)... ... February 08, 2016 , ... FileHold's document management ... DocuSyst provides a cloud hosted environment for FileHold software that is pay per ... 3rd party applications using the FileHold web services API. DocuSyst also advises clients ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... greater than 50% lower incidence rate of type 2 diabetes in the GrassrootsHealth ... ”It is time to make a change in public health,” states Carole Baggerly, ...
Breaking Medicine News(10 mins):